We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2004 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00066547
First Posted: August 7, 2003
Last Update Posted: December 4, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
August 6, 2003
August 7, 2003
December 4, 2013
May 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00066547 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy
An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and Taxane Therapy

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I/II trial to study the effect of monoclonal antibody therapy on the body and its effectiveness in treating women who have locally advanced or metastatic breast cancer that was previously treated with combination chemotherapy.

OBJECTIVES:

  • Determine the safety and tolerability of monoclonal antibody HuHMFG1 in women with locally advanced or metastatic breast cancer previously treated with anthracycline and taxane-based therapy.
  • Determine the maximum tolerated dose and appropriate schedule of this drug in these patients.
  • Determine the pharmacokinetic profile of this drug in these patients.
  • Determine the tumor response rate, progression-free survival, and median survival of patients treated with this drug.
  • Analyze immunological markers for evaluation of disease status (e.g., in vitro analysis of antibody-dependent cellular cytotoxicity, natural killer cell activity, complement depletion, and tumor markers CA 15.3 and CEA) in patients treated with this drug.

OUTLINE: This is a dose-escalation, open-label, nonrandomized, multicenter study.

  • Phase I: Patients receive monoclonal antibody HuHMFG1 IV over 1-3 hours once every 3 weeks for doses 1 and 2. All subsequent dose intervals are based on individual half-life value of the drug. Patients receive at least 6 doses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of monoclonal antibody HuHMFG1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

  • Phase II:Patients receive monoclonal antibody HuHMFG1 as above at the MTD. Patients are followed at 28 days.

PROJECTED ACCRUAL: Approximately 3-40 patients (3-15 patients for phase I and 19-25 patients for phase II) will be accrued for this study within approximately 12 months.

Interventional
Phase 1
Phase 2
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
Biological: monoclonal antibody HuHMFG1
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed breast cancer

    • Locally advanced or metastatic disease
    • No inflammatory breast cancer
  • Polymorphic epithelial mucin (PEM) antigen overexpression by immunohistochemistry
  • Previously treated with an anthracycline and a taxane in any combination for breast cancer

    • No more than 2 prior chemotherapy regimens, including adjuvant /neoadjuvant therapy
    • No more than 1 prior regimen for distant metastatic disease
    • Any number of prior hormonal or biologic therapy regimens allowed
  • Measurable disease

    • At least one unidimensionally measurable lesion not previously irradiated
    • The following are not considered measurable lesions:

      • Bone
      • Leptomeningeal disease
      • Ascites
      • Pleural/pericardial effusion
      • Lymphangitis cutis/pulmonis
      • Abdominal masses not confirmed and followed by imaging techniques
      • Cystic lesions
  • No metastases accessible to complete surgical resection
  • No CNS metastasis by CT scan
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Sex

  • Female

Menopausal status

  • Not specified

Performance status

  • WHO 0-2

Life expectancy

  • At least 4 months

Hematopoietic

  • Hemoglobin at least 10 g/dL
  • Neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic

  • Bilirubin no greater than 1.5 mg/dL
  • ALT and AST no greater than 2.5 times upper limit of normal (ULN) (less than 5 times ULN if liver metastases are present)

Renal

  • Creatinine no greater than 1.5 times ULN OR
  • Creatinine clearance greater than 60 mL/min
  • No hyperuricemia (uric acid at least 1.25 times ULN)
  • No hypercalcemia (calcium at least 11.5 mg/dL [corrected for serum albumin])

Cardiovascular

  • LVEF at least 45% by MUGA or echocardiogram within the past 4 weeks

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3-6 months after study participation
  • No other prior malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or cervical intraepithelial neoplasia
  • No other concurrent uncontrolled comorbid illness that represents unacceptable risk in the opinion of the investigator
  • No legal incapacity

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • More than 2 weeks since prior growth factors to aid hematologic recovery
  • No other concurrent immunotherapy

Chemotherapy

  • See Disease Characteristics
  • More than 4 weeks since prior cytotoxic chemotherapy
  • No concurrent chemotherapy for metastatic breast cancer

Endocrine therapy

  • See Disease Characteristics
  • No concurrent endocrine therapy for metastatic breast cancer
  • No concurrent chronic corticosteroid therapy
  • No concurrent high-dose corticosteroids

Radiotherapy

  • More than 4 weeks since prior radiotherapy except for palliation
  • No concurrent antitumor radiotherapy except for palliation

Surgery

  • More than 4 weeks since prior major surgery

Other

  • More than 2 weeks since prior blood transfusions to aid hematologic recovery
  • No participation in any other investigational drug study
  • No other concurrent investigational drugs
  • No other concurrent antitumor therapy
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00066547
CDR0000316264
UCLA-0212097
ANTISOMA-TOPCAT
ANTISOMA-ASM-THEREX-01
Not Provided
Not Provided
Not Provided
Not Provided
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Mark D. Pegram, MD Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
August 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP